2010 U.S. Sales: $3.5 billion
Company: Takeda Pharmaceuticals
Actos is meant to improve blood sugar control in adults with Type 2 diabetes.
The patent expired in January of 2011, but Japan-based Takeda came to an agreement with generic drug makers Ranbaxy (RBXZF) of India and Watson Pharmaceuticals (WPI) and Mylan (MYL) of the U.S., delaying the release of a generic version until August 2012.